Diabetes Drug Recall 2021: Another Metformin Recall Issued Over Possible Cancer Risks

After issuing a recall in November for four lots of medication, Nostrum Laboratories has recalled another lot of its diabetes drug Metformin. The latest recall stems from the drug containing higher than acceptable levels of a cancer-causing ingredient allowed by the U.S. Food and Drug Administration (FDA).

The recall affects Metformin HCl Extended Release Tablets with a 750 mg dosage.

The drug was found to have Nitrosodimethylamine (NDMA) impurities – a probable human carcinogen that could cause cancer – above the acceptable daily intake limit of 96 nanograms, as published by the FDA in September.

Metformin is used to improve blood glucose control in adults with Type 2 diabetes mellitus.

The affected drug was packed in bottles of 100 tablets with an NDC number of 29033-056-01. It has a lot number of MET200501 and an expiration date of July 2022. The medication is the generic equivalent to Glucophage tablets. The medication can be identified as off-white, oblong tablets that are debossed with NM7.

Consumers that have been prescribed the recalled Metformin tablets should contact their healthcare professional to obtain a replacement medication or a different treatment plan. Patients with Type 2 diabetes should talk to their physician before stopping the medication as the risk could be greater than continuing the prescription.

Nostrum Laboratories said it has not received any reports of adverse reactions related to the recall of the Metformin medication. Those that have experienced any problems related to taking the drug should contact their healthcare provider.

Questions about the recall can be directed to Nostrum Laboratories Medical Affairs at 1-816-308-4941, Monday through Friday from 8 a.m. to 5 p.m. CST or by email at quality@nostrumpharma.com.

The pull from Nostrum Laboratories follows a string of 2020 recalls from a number of pharmaceutical companies for the diabetes drug Metformin over the cancer-causing ingredient NDMA being at higher than acceptable levels.